株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

糖尿病治療装置市場:成長率、動向および予測(2012年~2024年)

Diabetes Care Devices Market - Growth, Trends, and Forecast (2012 - 2024)

発行 Mordor Intelligence LLP 商品コード 390762
出版日 ページ情報 英文 110 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
糖尿病治療装置市場:成長率、動向および予測(2012年~2024年) Diabetes Care Devices Market - Growth, Trends, and Forecast (2012 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 110 Pages
概要

世界の糖尿病治療装置市場は、予測期間(2019年~2023年)中に約6.8%のCAGRで成長すると予想されています。

当レポートでは、世界の糖尿病治療装置市場を調査し、全体的な市場動向、モニタリングデバイス・管理デバイス・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルおよびシェアなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
  • 市場阻害要因
  • ポーターのファイブフォース分析
    • 売り手の交渉力
    • 買い手の交渉力
    • 新規参入者の脅威
    • 代替製品およびサービスの脅威
    • 競争の激しさ

第5章 市場セグメンテーション

  • モニタリングデバイス
    • 血中グルコース自己監視装置
    • 持続的血糖モニタリング
  • 管理デバイス
    • インスリンポンプ
    • インスリン注射器
    • インスリンカートリッジ
    • 使い捨てペン
    • ジェットインジェクター
  • 地域
    • 北米
    • 欧州
    • ラテンアメリカ
    • アジア太平洋地域
    • 中東・アフリカ

第6章 市場指標

  • 1型糖尿病人口(2012年~2012年)
  • 2型糖尿病人口(2012年~2012年)

第7章 競合情勢

  • 企業プロファイル
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Dexcom
    • Medtronic
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業シェア分析
    • Roche
    • Johnson & Johnson
    • Abbott Diabetes Care
    • Dexcom
    • Medtronic
    • Novo Nordisk
    • Eli Lilly
    • Sanofi
    • その他

第8章 市場機会および将来動向

目次
Product Code: 49436

Market Overview

The global diabetes care devices market is expected to register a CAGR of about 6.8% during the forecast period (2019 - 2023).

Asia-Pacific is anticipated to dominate the market during the forecast period, owing to rising prevalence of obesity in the region.

There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.

Technological innovations and advances give much convenience in measuring the blood glucose levels. One such advancement in monitoring the blood glucose levels is established with continuous glucose monitoring devices.

Scope of the Report

The global diabetes care devices market is segmented by management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood glucose (hospital and personal use) and continuous glucose monitoring), and geography.

Key Market Trends - Rising Prevalence of Diabetes

As per a WHO report, the global prevalence of diabetes among adults of over 18 years accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.

Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.

Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh-leading cause of death by 2030.

The growing prevalence of diabetes is the major driver for the global diabetes care devices market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market for diabetes care devices.

North America to Dominate the Monitoring Devices Segment

The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles.

Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness regarding diabetic care.

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of few strategic outcomes include:

In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for diabetics aged between aged between 14-75 years.

In January 2018, Abbott announced that the FreeStyleLibre System, the company's revolutionary new continuous glucose monitoring (CGM) system, was available to Medicare patients in the United States.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation

  • 5.1 Monitoring Devices
    • 5.1.1 Self-Monitoring Blood Glucose Devices
      • 5.1.1.1 By Component (Value and Volume, 2012 - 2024)
      • 5.1.1.1.1 Glucometer Devices
      • 5.1.1.1.2 Test Strips
      • 5.1.1.1.3 Lancets
      • 5.1.1.2 By End User
      • 5.1.1.2.1 Hospital (Value and Volume, 2012 - 2024)
      • 5.1.1.2.1.1 Glucometer Devices
      • 5.1.1.2.1.2 Test Strips
      • 5.1.1.2.1.3 Lancets
      • 5.1.1.2.2 Personal (Value and Volume, 2012 - 2024)
      • 5.1.1.2.2.1 Glucometer Devices
      • 5.1.1.2.2.2 Test Strips
      • 5.1.1.2.2.3 Lancets
    • 5.1.2 Continuous Blood Glucose Monitoring
      • 5.1.2.1 By Component (Value and Volume, 2012 - 2024)
      • 5.1.2.1.1 Sensors
      • 5.1.2.1.2 Receivers
  • 5.2 Management Devices
    • 5.2.1 Insulin Pump
      • 5.2.1.1 Insulin Pump Device
      • 5.2.1.2 Insulin Pump Reservoir
      • 5.2.1.3 Infusion Set
    • 5.2.2 Insulin Syringes
    • 5.2.3 Insulin Cartridges
    • 5.2.4 Disposable Pens
    • 5.2.5 Jet Injectors
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (Value and Volume, 2012 - 2024)
      • 5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.1.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.1.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.1.2 Canada (Value and Volume, 2012 - 2024)
      • 5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.1.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.1.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.1.3 Rest of North America (Value and Volume, 2012 - 2024)
      • 5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.1.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.1.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.2 Europe
      • 5.3.2.1 France (Value and Volume, 2012 - 2024)
      • 5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.2 Germany (Value and Volume, 2012 - 2024)
      • 5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.3 Italy (Value and Volume, 2012 - 2024)
      • 5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.4 Spain (Value and Volume, 2012 - 2024)
      • 5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.5 United Kingdom (Value and Volume, 2012 - 2024)
      • 5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.6 Russia (Value and Volume, 2012 - 2024)
      • 5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2024)
      • 5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.3 Latin America
      • 5.3.3.1 Mexico (Value and Volume, 2012 - 2024)
      • 5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.3.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.3.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.3.2 Brazil (Value and Volume, 2012 - 2024)
      • 5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.3.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.3.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2024)
      • 5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.3.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.3.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.4 Asia-Pacific
      • 5.3.4.1 Japan (Value and Volume, 2012 - 2024)
      • 5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.2 South Korea (Value and Volume, 2012 - 2024)
      • 5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.3 China (Value and Volume, 2012 - 2024)
      • 5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.4 India (Value and Volume, 2012 - 2024)
      • 5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.5 Australia (Value and Volume, 2012 - 2024)
      • 5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.6 Vietnam (Value and Volume, 2012 - 2024)
      • 5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.7 Malaysia (Value and Volume, 2012 - 2024)
      • 5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.8 Indonesia (Value and Volume, 2012 - 2024)
      • 5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.8.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.8.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.9 Philippines (Value and Volume, 2012 - 2024)
      • 5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.9.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.9.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.10 Thailand (Value and Volume, 2012 - 2024)
      • 5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.10.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.10.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2024)
      • 5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.11.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.11.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.5 Middle East & Africa
      • 5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2024)
      • 5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.2 Iran (Value and Volume, 2012 - 2024)
      • 5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.3 Egypt (Value and Volume, 2012 - 2024)
      • 5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.4 Oman (Value and Volume, 2012 - 2024)
      • 5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.5 South Africa (Value and Volume, 2012 - 2024)
      • 5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 - 2024)
      • 5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2024)
  • 6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Dexcom
    • 7.1.5 Medtronic
    • 7.1.6 Arkray
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon
    • 7.1.11 Medisana
    • 7.1.12 Trivida
    • 7.1.13 Rossmax
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Roche
    • 7.2.2 Johnson & Johnson
    • 7.2.3 Abbott Diabetes Care
    • 7.2.4 Dexcom
    • 7.2.5 Medtronic
    • 7.2.6 Novo Nordisk
    • 7.2.7 Eli Lilly
    • 7.2.8 Sanofi
    • 7.2.9 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top